{"id":34025,"date":"2025-11-24T16:51:00","date_gmt":"2025-11-24T11:21:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=34025"},"modified":"2025-11-21T15:09:42","modified_gmt":"2025-11-21T09:39:42","slug":"gene-therapy-for-huntingtons-disease-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-huntingtons-disease-treatment","title":{"rendered":"Huntington\u2019s Disease Treatment Meets Its Match: Gene Therapy in Action"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a14bf619ca4f\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a14bf619ca4f\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-huntingtons-disease-treatment\/#Huntingtons_Disease_Genetics_Symptoms_and_Therapeutic_Gaps\" >Huntington\u2019s Disease: Genetics, Symptoms, and Therapeutic Gaps<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-huntingtons-disease-treatment\/#Global_Impact_Expanding_Huntingtons_Disease_Population_and_Clinical_Demand\" >Global Impact: Expanding Huntington\u2019s Disease Population and Clinical Demand<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-huntingtons-disease-treatment\/#AMT-130_uniQures_Bold_Attempt_to_Rewrite_Huntingtons_Biology\" >AMT-130: uniQure\u2019s Bold Attempt to Rewrite Huntington\u2019s Biology<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-huntingtons-disease-treatment\/#Regulatory_Status\" >Regulatory Status<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-huntingtons-disease-treatment\/#Clinical_Development_Program\" >Clinical Development Program<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-huntingtons-disease-treatment\/#Topline_Phase_III_Results\" >Topline Phase I\/II Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-huntingtons-disease-treatment\/#Key_Insights_from_the_Results\" >Key Insights from the Results<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-huntingtons-disease-treatment\/#Beyond_uniQure_A_Crowded_and_Creative_Pipeline_for_Huntingtons_Disease_Treatment\" >Beyond uniQure: A Crowded and Creative Pipeline for Huntington\u2019s Disease Treatment<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-huntingtons-disease-treatment\/#RocheSpark_Therapeutics_%E2%80%93_SPK-10001_RG6662\" >Roche\/Spark Therapeutics \u2013 SPK-10001 (RG6662)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-huntingtons-disease-treatment\/#Latus_Bio_%E2%80%93_LTS-201\" >Latus Bio \u2013 LTS-201<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-huntingtons-disease-treatment\/#SOLA_Biosciences_%E2%80%93_SOL-175\" >SOLA Biosciences \u2013 SOL-175<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-huntingtons-disease-treatment\/#VectorY_Therapeutics_%E2%80%93_VTx-003\" >VectorY Therapeutics \u2013 VTx-003<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-huntingtons-disease-treatment\/#NovartisVoyager_Therapeutics_Collaboration\" >Novartis\/Voyager Therapeutics Collaboration<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-huntingtons-disease-treatment\/#The_Takeaway_From_Symptom_Control_to_Disease_Modification\" >The Takeaway: From Symptom Control to Disease Modification<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-huntington-s-disease-genetics-symptoms-and-therapeutic-gaps\"><span class=\"ez-toc-section\" id=\"Huntingtons_Disease_Genetics_Symptoms_and_Therapeutic_Gaps\"><\/span><strong>Huntington\u2019s Disease: Genetics, Symptoms, and Therapeutic Gaps<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Huntington\u2019s disease is often described as having <strong>Amyotrophic Lateral Sclerosis<\/strong> <strong>(ALS), Parkinson\u2019s, and Alzheimer\u2019s rolled into one<\/strong>\u2014a neurodegenerative triple threat that devastates motor control, cognition, and behavior in a single blow. Caused by the expansion of <strong>CAG repeats in the <\/strong><strong><em>HTT<\/em><\/strong><strong> gene<\/strong>, the disease produces toxic huntingtin protein aggregates that progressively destroy neurons. Onset typically strikes between 30 and 50 years of age, though longer repeats can trigger the even more aggressive <strong>juvenile form (&lt;20 years)<\/strong>.<\/p>\n\n\n\n<p>Inheritance is unforgiving: each child of an affected parent has a 50% risk, and paternal transmission often accelerates onset across generations through genetic anticipation. Once Huntington\u2019s disease symptoms begin, chorea, psychiatric decline, and memory loss, the trajectory is inescapable. Diagnosis relies on clinical suspicion, confirmed by genetic testing and supported by counseling for families who must decide whether to undergo predictive testing.<\/p>\n\n\n\n<p>Yet despite decades of research, Huntington\u2019s disease remains incurable. Care today is multidisciplinary and supportive, encompassing physiotherapy, occupational therapy, and speech therapy, as well as psychiatric care, but the best it can offer is a reprieve. <strong>VMAT2 inhibitors<\/strong> such as <strong>AUSTEDO (deutetrabenazine)<\/strong> and <a href=\"https:\/\/www.delveinsight.com\/blog\/huntingtons-disease-treatment\"><strong>INGREZZA (valbenazine)<\/strong><\/a> help regulate dopamine signaling and ease chorea, but they cannot slow neuronal death or alter the course of disease. Patients eventually become fully dependent on caregivers. The therapeutic gap is glaring: symptomatic relief without disease modification.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-global-impact-expanding-huntington-s-disease-population-and-clinical-demand\"><span class=\"ez-toc-section\" id=\"Global_Impact_Expanding_Huntingtons_Disease_Population_and_Clinical_Demand\"><\/span><strong>Global Impact: Expanding Huntington\u2019s Disease Population and Clinical Demand<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>According to DelveInsight, around <strong>82,000 individuals<\/strong> were <a href=\"https:\/\/www.delveinsight.com\/report-store\/huntingtons-disease-epidemiology-forecast\">living with Huntington\u2019s disease<\/a> across the major markets (the US, Germany, France, Italy, Spain, the UK, and Japan) in 2024. This number is expected to rise steadily, not because the disease is spreading, but because diagnosis is improving, supportive care extends survival, and awareness among clinicians and at-risk families is growing.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/sample-request\/huntingtons-disease-market\"><img decoding=\"async\" width=\"1024\" height=\"465\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/20165009\/Huntingtons-Disease-Epidemiology-Assessment-1024x465.webp\" alt=\"Huntingtons-Disease-Epidemiology-Assessment\" class=\"wp-image-34031\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/20165009\/Huntingtons-Disease-Epidemiology-Assessment-1024x465.webp 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/20165009\/Huntingtons-Disease-Epidemiology-Assessment-300x136.webp 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/20165009\/Huntingtons-Disease-Epidemiology-Assessment-150x68.webp 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/20165009\/Huntingtons-Disease-Epidemiology-Assessment-768x348.webp 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/20165009\/Huntingtons-Disease-Epidemiology-Assessment-1536x697.webp 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/20165009\/Huntingtons-Disease-Epidemiology-Assessment.webp 1920w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p>Aging populations are also unmasking late-onset Huntington\u2019s disease cases, while genetic testing increasingly identifies pre-symptomatic carriers. Together, these forces ensure that prevalence and the demand for effective therapies will only continue to climb.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-amt-130-uniqure-s-bold-attempt-to-rewrite-huntington-s-biology\"><span class=\"ez-toc-section\" id=\"AMT-130_uniQures_Bold_Attempt_to_Rewrite_Huntingtons_Biology\"><\/span><strong>AMT-130: uniQure\u2019s Bold Attempt to Rewrite Huntington\u2019s Biology<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>For the first time, drug developers are aiming not at symptoms but at the genetic root. <strong>uniQure\u2019s AMT-130<\/strong> stands at the front of this revolution.<\/p>\n\n\n\n<p><strong>The strategy:<\/strong> use an <strong>AAV5 vector<\/strong> to deliver an artificial microRNA directly into the striatum\u2014the brain\u2019s epicenter of Huntington\u2019s disease pathology. Administered via MRI-guided, convection-enhanced neurosurgery, the therapy silences both the full-length mutant <em>HTT<\/em> and the highly toxic exon-1 fragment. The vision is <strong>one-time dosing with long-lasting impact<\/strong>, resetting the disease trajectory at its source.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-regulatory-status\"><span class=\"ez-toc-section\" id=\"Regulatory_Status\"><\/span><strong>Regulatory Status<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The US FDA has recognized AMT-130 for its potential to address the significant unmet medical needs in Huntington\u2019s disease, receiving multiple expedited designations.<\/p>\n\n\n\n<p><strong>Breakthrough Therapy<\/strong> (April 2025): Acknowledges AMT-130\u2019s potential to demonstrate substantial improvement over existing therapies.<\/p>\n\n\n\n<p><strong>Regenerative Medicine Advanced Therapy<\/strong> (RMAT, June 2024): The first RMAT designation for Huntington\u2019s disease, facilitating closer collaboration with the US FDA and accelerated development.<\/p>\n\n\n\n<p><strong>Fast Track<\/strong> (April 2019): Supports faster review and more frequent interactions with the FDA to expedite development.<\/p>\n\n\n\n<p><strong>Orphan Drug<\/strong> (US and EU): Recognizes AMT-130 as a therapy for a rare condition, providing incentives for development and regulatory support.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-clinical-development-program\"><span class=\"ez-toc-section\" id=\"Clinical_Development_Program\"><\/span><strong>Clinical Development Program<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The AMT-130 program consists of multi-center, dose-escalating Phase I\/II studies in the U.S. and Europe, enrolling patients with early manifest Huntington\u2019s disease. Key aspects include<\/p>\n\n\n\n<p><strong>US study:<\/strong> 26 patients randomized to low dose (n = 6), high dose (n = 10), or sham procedure (n = 10). A blinded 12-month core study followed by a 5-year long-term follow-up.<\/p>\n\n\n\n<p><strong>European open-label study:<\/strong> 13 patients (low dose n = 6; high dose n = 7)<\/p>\n\n\n\n<p>Additional cohorts evaluated dose escalation, combination with immunosuppression, and patients with lower striatal volumes.<\/p>\n\n\n\n<p>Clinical outcomes were compared to a propensity score-matched external control derived from the Enroll-HD natural history study, acting as a virtual placebo to assess disease-modifying effects.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-topline-phase-i-ii-results\"><span class=\"ez-toc-section\" id=\"Topline_Phase_III_Results\"><\/span><strong>Topline Phase I\/II Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>In <strong>September 2025<\/strong>, uniQure announced positive 36-month topline results for high-dose AMT-130.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Measure\/ Endpoint<\/strong><\/td><td><strong>AMT-130 High Dose Outcome<\/strong><\/td><td><strong>Expected Without Treatment (External Control)<\/strong><\/td><td><strong>Effect\/Interpretation<\/strong><\/td><td><strong>Statistical Significance<\/strong><\/td><\/tr><tr><td><strong>Composite Unified Huntington\u2019s Disease Rating Scale (cUHDRS)<\/strong><\/td><td>\u20130.38<\/td><td>\u20131.52<\/td><td>75% slower disease progression<\/td><td><em>p<\/em> = 0.003<\/td><\/tr><tr><td><strong>Total Functional Capacity (TFC)<\/strong><\/td><td>\u20130.36<\/td><td>\u20130.88<\/td><td>60% slower decline in daily functioning<\/td><td><em>p<\/em> = 0.033<\/td><\/tr><tr><td><strong>Symbol Digit Modality Test (SDMT)<\/strong><\/td><td>-0.44<\/td><td>\u20133.73<\/td><td>88% slower cognitive decline<\/td><td><em>p<\/em> = 0.057 (trend)<\/td><\/tr><tr><td><strong>Stroop Word Reading Test (SWRT)<\/strong><\/td><td>0.88<\/td><td>\u20136.98<\/td><td>113% improvement \/ slower cognitive decline<\/td><td><em>p<\/em> = 0.002<\/td><\/tr><tr><td><strong>Total Motor Score (TMS)<\/strong><\/td><td>2.01<\/td><td>4.88<\/td><td>59% slower worsening of motor symptoms<\/td><td><em>p<\/em> = 0.174 (trend)<\/td><\/tr><tr><td><strong>Cerebrospinal Fluid Neurofilament Light (CSF NfL)<\/strong><\/td><td>\u20138.2%<\/td><td>&#8211;<\/td><td>Supports reduced neurodegeneration<\/td><td>&#8211;<\/td><\/tr><tr><td><strong>Safety\/Tolerability<\/strong><\/td><td>Well-tolerated; procedure-related AEs resolved<\/td><td>&#8211;<\/td><td>Manageable safety profile<\/td><td>&#8211;<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-key-insights-from-the-results\"><span class=\"ez-toc-section\" id=\"Key_Insights_from_the_Results\"><\/span><strong>Key Insights from the Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Significant slowing of disease progression across multiple functional, motor, and cognitive measures, particularly at high doses.<\/li>\n\n\n\n<li>Dose-dependent response observed: High dose consistently outperformed low dose.<\/li>\n\n\n\n<li>CSF NfL reduction supports the biological effect in slowing neurodegeneration.<\/li>\n\n\n\n<li>The safety profile was manageable, with adverse events largely associated with the administration procedure, all of which resolved.<\/li>\n<\/ul>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-beyond-uniqure-a-crowded-and-creative-pipeline-for-huntington-s-disease-treatment\"><span class=\"ez-toc-section\" id=\"Beyond_uniQure_A_Crowded_and_Creative_Pipeline_for_Huntingtons_Disease_Treatment\"><\/span><strong>Beyond uniQure: A Crowded and Creative Pipeline for Huntington\u2019s Disease Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>While AMT-130 leads, it is far from alone. The <a href=\"https:\/\/www.delveinsight.com\/report-store\/huntingtons-disease-pipeline-insight\">Huntington\u2019s disease clinical trial pipeline<\/a> reflects a <strong>diverse, high-stakes race to crack the genetic code of neurodegeneration:<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-roche-spark-therapeutics-spk-10001-rg6662\"><span class=\"ez-toc-section\" id=\"RocheSpark_Therapeutics_%E2%80%93_SPK-10001_RG6662\"><\/span><strong>Roche\/Spark Therapeutics \u2013 SPK-10001 (RG6662)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>A microRNA therapy silencing <em>HTT<\/em>, now in Phase I\/II, reflects Roche\u2019s long-term bet following its USD 4.3 billion acquisition of Spark Therapeutics in 2019. Leveraging Spark\u2019s gene therapy expertise, Roche is advancing SPK-10001, with the first patient already dosed in ongoing trials.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-latus-bio-lts-201\"><span class=\"ez-toc-section\" id=\"Latus_Bio_%E2%80%93_LTS-201\"><\/span><strong>Latus Bio \u2013 LTS-201<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Targets <em>MSH3<\/em>, a DNA repair enzyme that fuels somatic CAG expansion, rather than <em>HTT<\/em> directly. Preclinical data show reduced expansion in mice, and its AAV-DB-3 capsid has demonstrated efficient delivery to deep brain structures, long a bottleneck for gene therapy.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-sola-biosciences-sol-175\"><span class=\"ez-toc-section\" id=\"SOLA_Biosciences_%E2%80%93_SOL-175\"><\/span><strong>SOLA Biosciences \u2013 SOL-175<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Uses proprietary JUMP70 technology to modulate the folding of mutant <em>HTT<\/em>\u2019s polyQ stretches without disturbing normal <em>HTT<\/em>. Still preclinical, but it represents a precision strategy aimed at restoring protein balance.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/sample-request\/huntingtons-disease-market\"><img decoding=\"async\" width=\"1024\" height=\"443\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/20164943\/Huntingtons-emerging-gene-therapies-1024x443.webp\" alt=\"Huntingtons-emerging-gene-therapies\" class=\"wp-image-34030\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/20164943\/Huntingtons-emerging-gene-therapies-1024x443.webp 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/20164943\/Huntingtons-emerging-gene-therapies-300x130.webp 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/20164943\/Huntingtons-emerging-gene-therapies-150x65.webp 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/20164943\/Huntingtons-emerging-gene-therapies-768x332.webp 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/20164943\/Huntingtons-emerging-gene-therapies-1536x664.webp 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/20164943\/Huntingtons-emerging-gene-therapies.webp 1920w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-vectory-therapeutics-vtx-003\"><span class=\"ez-toc-section\" id=\"VectorY_Therapeutics_%E2%80%93_VTx-003\"><\/span><strong>VectorY Therapeutics \u2013 VTx-003<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>A vectorized antibody that selectively clears mutant <em>HTT<\/em>. In partnership with Shape Therapeutics, VectorY has access to novel AAV5-derived CNS capsids capable of deep-brain penetration via IV delivery\u2014a potential game-changer for non-invasive administration.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-novartis-voyager-therapeutics-collaboration\"><span class=\"ez-toc-section\" id=\"NovartisVoyager_Therapeutics_Collaboration\"><\/span><strong>Novartis\/Voyager Therapeutics Collaboration<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Through Voyager\u2019s TRACER AAV platform, Novartis is evaluating next-generation capsids for CNS disorders, including an undisclosed Huntington\u2019s disease program. The goal: overcome current distribution challenges and open the door to more efficient brain-wide delivery.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-takeaway-from-symptom-control-to-disease-modification\"><span class=\"ez-toc-section\" id=\"The_Takeaway_From_Symptom_Control_to_Disease_Modification\"><\/span><strong>The Takeaway: From Symptom Control to Disease Modification<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>For decades, Huntington\u2019s disease has epitomized therapeutic frustration: a devastating genetic disorder, relentless progression, and limited options beyond symptom management. That <a href=\"https:\/\/www.delveinsight.com\/report-store\/huntingtons-disease-market\">Huntington\u2019s disease treatment landscape<\/a> is now changing.<\/p>\n\n\n\n<p>Gene therapies such as <strong>AMT-130<\/strong> represent the first concerted efforts to alter the natural course of Huntington\u2019s disease rather than merely mitigate its symptoms. The broader pipeline, including strategies to silence the <em>HTT<\/em> gene, block CAG expansions, or deploy vectorized antibodies, marks a new era of molecular neurology, focusing on addressing the root cause rather than its consequences.<\/p>\n\n\n\n<p>The coming years will be critical in defining the regulatory and commercial path for <a href=\"https:\/\/www.delveinsight.com\/report-store\/huntingtons-disease-pipeline-insight\">Huntington\u2019s disease gene therapies<\/a>. For AMT-130, key near-term milestones include a pre-Biologics License Application (BLA) meeting with the US FDA in the <strong>fourth quarter of 2025<\/strong>, followed by a planned BLA submission in the <strong>first quarter of 2026<\/strong> with a request for priority review. If approved, a US launch could take place later in <strong>2026<\/strong>, potentially marking the first disease-modifying therapy for Huntington\u2019s disease.<\/p>\n\n\n\n<p>Should these programs fulfill their promise, the field could finally shift from merely \u201c<strong>managing decline<\/strong>\u201d <strong>to changing the disease trajectory<\/strong>\u2014a transformative moment for patients, families, and the future of neurodegenerative medicine.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/huntingtons-disease-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/20164903\/Huntingtons-Disease-Market-Assessment-1024x194.webp\" alt=\"Huntingtons Disease Market Assessment\" class=\"wp-image-34029\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/20164903\/Huntingtons-Disease-Market-Assessment-1024x194.webp 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/20164903\/Huntingtons-Disease-Market-Assessment-300x57.webp 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/20164903\/Huntingtons-Disease-Market-Assessment-150x28.webp 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/20164903\/Huntingtons-Disease-Market-Assessment-768x145.webp 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/20164903\/Huntingtons-Disease-Market-Assessment-1536x291.webp 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/20164903\/Huntingtons-Disease-Market-Assessment.webp 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Huntington\u2019s Disease: Genetics, Symptoms, and Therapeutic Gaps Huntington\u2019s disease is often described as having Amyotrophic Lateral Sclerosis (ALS), Parkinson\u2019s, and Alzheimer\u2019s rolled into one\u2014a neurodegenerative triple threat that devastates motor control, cognition, and behavior in a single blow. Caused by the expansion of CAG repeats in the HTT gene, the disease produces toxic huntingtin protein [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":34027,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[305,22769,12745,12744,12746],"industry":[17225],"therapeutic_areas":[17238],"class_list":["post-34025","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-huntingtons-disease","tag-huntingtons-disease-gene-therapy","tag-huntingtons-disease-market","tag-huntingtons-disease-pipeline","tag-huntingtons-disease-treatment","industry-pharmaceutical","therapeutic_areas-genetic-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Gene Therapy\u2019s Promise in Huntington\u2019s Disease Treatment<\/title>\n<meta name=\"description\" content=\"Huntington\u2019s disease treatment landscape is now changing with the introduction of novel gene therapies by leading pharma giants.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-huntingtons-disease-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gene Therapy\u2019s Promise in Huntington\u2019s Disease Treatment\" \/>\n<meta property=\"og:description\" content=\"Huntington\u2019s disease treatment landscape is now changing with the introduction of novel gene therapies by leading pharma giants.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-huntingtons-disease-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-24T11:21:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/20164816\/gene-therapy-for-huntingtons-disease-treatment.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gene Therapy\u2019s Promise in Huntington\u2019s Disease Treatment","description":"Huntington\u2019s disease treatment landscape is now changing with the introduction of novel gene therapies by leading pharma giants.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-huntingtons-disease-treatment","og_locale":"en_US","og_type":"article","og_title":"Gene Therapy\u2019s Promise in Huntington\u2019s Disease Treatment","og_description":"Huntington\u2019s disease treatment landscape is now changing with the introduction of novel gene therapies by leading pharma giants.","og_url":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-huntingtons-disease-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-11-24T11:21:00+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/20164816\/gene-therapy-for-huntingtons-disease-treatment.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-huntingtons-disease-treatment","url":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-huntingtons-disease-treatment","name":"Gene Therapy\u2019s Promise in Huntington\u2019s Disease Treatment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-huntingtons-disease-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-huntingtons-disease-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/20164816\/gene-therapy-for-huntingtons-disease-treatment.webp","datePublished":"2025-11-24T11:21:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Huntington\u2019s disease treatment landscape is now changing with the introduction of novel gene therapies by leading pharma giants.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-huntingtons-disease-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-huntingtons-disease-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/20164816\/gene-therapy-for-huntingtons-disease-treatment.webp","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/20164816\/gene-therapy-for-huntingtons-disease-treatment.webp","width":466,"height":284,"caption":"gene-therapy-for-huntingtons-disease-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/20164816\/gene-therapy-for-huntingtons-disease-treatment-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Huntington\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Huntington\u2019s Disease Gene Therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Huntington\u2019s disease Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Huntington\u2019s disease Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Huntington\u2019s disease Treatment<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Huntington\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">Huntington\u2019s Disease Gene Therapy<\/span>","<span class=\"advgb-post-tax-term\">Huntington\u2019s disease Market<\/span>","<span class=\"advgb-post-tax-term\">Huntington\u2019s disease Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Huntington\u2019s disease Treatment<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 months ago","modified":"Updated 6 months ago"},"absolute_dates":{"created":"Posted on Nov 24, 2025","modified":"Updated on Nov 21, 2025"},"absolute_dates_time":{"created":"Posted on Nov 24, 2025 4:51 pm","modified":"Updated on Nov 21, 2025 3:09 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34025","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=34025"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34025\/revisions"}],"predecessor-version":[{"id":34032,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34025\/revisions\/34032"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/34027"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=34025"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=34025"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=34025"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=34025"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=34025"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}